1. Home
  2. STTK vs TG Comparison

STTK vs TG Comparison

Compare STTK & TG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

HOLD

Current Price

$3.06

Market Cap

119.0M

Sector

Health Care

ML Signal

HOLD

Logo Tredegar Corporation

TG

Tredegar Corporation

HOLD

Current Price

$7.52

Market Cap

301.0M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
STTK
TG
Founded
2016
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Metal Fabrications
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
119.0M
301.0M
IPO Year
2020
1989

Fundamental Metrics

Financial Performance
Metric
STTK
TG
Price
$3.06
$7.52
Analyst Decision
Buy
Analyst Count
5
0
Target Price
$4.00
N/A
AVG Volume (30 Days)
224.7K
170.9K
Earning Date
11-06-2025
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,000,000.00
$691,173,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$115.18
Revenue Growth
N/A
43.30
52 Week Low
$0.69
$6.25
52 Week High
$3.12
$9.43

Technical Indicators

Market Signals
Indicator
STTK
TG
Relative Strength Index (RSI) 79.66 45.21
Support Level $1.93 $7.73
Resistance Level $2.18 $8.17
Average True Range (ATR) 0.20 0.29
MACD 0.12 -0.04
Stochastic Oscillator 98.42 5.83

Price Performance

Historical Comparison
STTK
TG

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

About TG Tredegar Corporation

Tredegar Corp, through its subsidiaries, engages in the manufacture of polyethylene plastic films, polyester films, and aluminum extrusions. Polyethylene plastic films produce plastic films, elastics, and laminate materials that are used in personal care products, surface protection films, and specialty and optical lighting applications. The company operates through segments including PE films, flexible packaging films, and aluminum extrusions. Aluminum extrusions generate the majority of revenue and provide high-quality, soft-alloy, medium-strength aluminum utilized in the building and construction, automotive, consumer durables, machinery and equipment, electrical, and distribution markets. Revenue is generated from the United States, Asia, and Brazil.

Share on Social Networks: